PCM
KALV

Penserra Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Penserra Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-560
Closed -$9K – 1454
2021
Q3 		$9K Buy
560
+5
+0.9% +$101 ﹤0.01% 1369
2021
Q2 		$13K Buy
555
+25
+5% +$654 ﹤0.01% 1253
2021
Q1 		$13K Buy
530
+120
+29% +$3.15K ﹤0.01% 1006
2020
Q4 		$7K Buy
+410
New +$7.03K ﹤0.01% 960

Other funds holding KALV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Penserra Capital Management's KALV Position: Q4 2021 in Review

Penserra Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q4 2021, closing a stake of 560 shares — an estimated $9K sold.

Penserra Capital Management first reported a position in KALV in Q4 2020 and held it in 4 quarters. The position peaked at $13K in Q2 2021. 97 funds tracked by Wall St. Rank hold KALV as of Q4 2021.

  • Penserra Capital Management reported no remaining KalVista Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 560 KalVista Pharmaceuticals shares in Q4 2021, an estimated $9K.
  • Penserra Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's KalVista Pharmaceuticals position peaked at $13K in Q2 2021.
  • 97 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.